Related Experiment Videos
Cerebral demyelination with 5-fluorouracil and levamisole
A B Fassas1, A M Gattani, S Morgello
1Department of Neoplastic Diseases, Jerald H. Ruttenberg Cancer Center, Mount Sinai Medical Center, New York, New York.
Cancer Investigation
|January 1, 1994
Summary
This case report details multifocal cerebral demyelination, a rare neurological side effect of adjuvant chemotherapy (5-fluorouracil, levamisole, leucovorin) for intestinal adenocarcinoma. Symptoms resolved after stopping treatment and steroid use.
Area of Science:
- Neuro-oncology
- Neurotoxicology
- Chemotherapy
Background:
- Adjuvant chemotherapy regimens including 5-fluorouracil, levamisole, and leucovorin are standard for intestinal adenocarcinoma.
- Neurological toxicities associated with these agents are uncommon but can be severe.
Observation:
- A patient receiving adjuvant chemotherapy developed acute confusion, restlessness, ataxia, and slurred speech.
- Neuroimaging revealed multifocal enhancing white matter lesions, confirmed as demyelination on brain biopsy.
Findings:
- The patient experienced clinical and radiological improvement after discontinuing chemotherapy and receiving corticosteroids.
- This represents one of the few reported cases of multifocal leukoencephalopathy linked to 5-fluorouracil and levamisole combination therapy.
Implications:
- Increased recognition of this rare neurological toxicity is warranted given the widespread use of these chemotherapeutic agents.
- Early identification and cessation of chemotherapy may lead to favorable outcomes in patients with chemotherapy-induced demyelination.